Correct Answer: D. Chemoradiation
This patient presents with locally advanced cervical cancer (LACC) — the clinical hallmark is a necrotizing growth with parametrial involvement, which defines FIGO stage IIB or higher. The foul-smelling bloody discharge and mucous are typical of an ulcerating cervical malignancy. Parametrial involvement is the critical discriminator: it indicates the tumor has breached the cervical stroma and invaded the parametrium, making it unresectable by simple hysterectomy alone.
For LACC (FIGO stage IB2–IVA), the gold standard of care is concurrent chemoradiation (CCRT), as established by landmark trials (RTOG 90-01, GOG 165) and endorsed by Indian guidelines (NCCN, ICMR). The rationale is twofold: (1) external beam radiotherapy (EBRT) targets the primary tumor and pelvic lymph nodes, and (2) concurrent chemotherapy (typically cisplatin 40 mg/m² weekly) acts as a radiosensitizer, improving local control and overall survival by ~10–15% compared to radiation alone. Brachytherapy is added after EBRT completion to boost the primary tumor dose.
Parametrial involvement precludes primary surgery because: (a) margins cannot be achieved without sacrificing vital structures (ureter, bladder, rectum), and (b) residual disease risk is prohibitively high. Thus, CCRT is the definitive curative approach in this setting, with 5-year survival rates of 60–70% in appropriately selected patients.
Why the other options are wrong
A. Chemotherapy — Chemotherapy alone is palliative, not curative, for LACC. It is reserved for metastatic or recurrent disease. In locally advanced disease, chemotherapy must be concurrent with radiation to act as a radiosensitizer and achieve locoregional control. Standalone chemotherapy lacks the dose intensity and local effect needed to control a bulky parametrial tumor. B. Brachytherapy — Brachytherapy alone is insufficient for LACC with parametrial involvement. Brachytherapy delivers high-dose radiation to the cervix and paracervical tissues but cannot adequately cover the pelvic sidewall and parametrium. It is used as a boost after EBRT completion, not as monotherapy. EBRT is mandatory first to treat the parametrium and pelvic nodes. C. Surgery — Primary surgery (radical hysterectomy with pelvic lymphadenectomy) is contraindicated in LACC with parametrial involvement because: (1) margins cannot be achieved without sacrificing bladder/rectum/ureter, (2) residual disease risk is unacceptably high, and (3) morbidity is severe. Surgery may be considered only for early-stage disease (IA–IB1) or as salvage for recurrent disease after CCRT.
High-Yield Facts
- FIGO stage IIB or higher (parametrial involvement) = LACC → concurrent chemoradiation is DOC, not surgery or RT alone.
- Cisplatin 40 mg/m² weekly during EBRT improves 5-year OS by ~10–15% vs. RT alone (landmark RTOG 90-01 trial).
- EBRT (45–50 Gy) + concurrent chemotherapy + brachytherapy boost (20–30 Gy) = standard CCRT regimen for LACC.
- Parametrial involvement = tumor has crossed cervical stroma into parametrium → unresectable, mandates radiation-based approach.
- Brachytherapy is never monotherapy for LACC; it is always a boost after EBRT to increase local dose to primary tumor.
Mnemonics
LACC Management: EBRT-CHEMO-BRACHY EBRT (external beam) + CHEMO (concurrent cisplatin) + BRACHY (brachytherapy boost). This is the sequence and the mantra for locally advanced cervical cancer. Use when you see parametrial involvement or FIGO ≥IIB. Parametrium = Radiation, Not Surgery If the tumor touches the parametrium, think radiation. Parametrial involvement = unresectable → CCRT is the only curative option. Surgery is off the table.
NBE Trap
NBE may lure students with parametrial involvement to choose surgery (confusing it with early-stage disease where radical hysterectomy is appropriate) or brachytherapy alone (forgetting that EBRT is mandatory for pelvic sidewall coverage). The trap is not recognizing that parametrial involvement = LACC = radiation-based, not surgery-based.
Clinical Pearl
In Indian tertiary centers, CCRT for LACC is increasingly accessible via government cancer institutes (AIIMS, TATA Memorial). A 50-year-old woman with parametrial involvement has a realistic 5-year cure rate of 60–70% with CCRT, whereas surgery alone would leave her with uncontrolled pelvic disease and severe morbidity. This is why parametrial involvement is the clinical red flag that shifts management from surgery to chemoradiation.
_Reference: DC Dutta's Textbook of Gynaecology (6th ed.), Ch. 19 (Cervical Cancer); Harrison's Principles of Internal Medicine, Ch. 87 (Gynecologic Malignancies); NCCN Clinical Practice Guidelines for Cervical Cancer (2023)._